Clinical trial
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and…
NCT02499770 · G1 Therapeutics, Inc., Industry · Completed
Key facts
| NCT number | NCT02499770 |
|---|---|
| Title | Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC) |
| Official title | Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin |
| Lead sponsor | G1 Therapeutics, Inc., Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Carboplatin, Placebo, Trilaciclib, Etoposide |
| Enrollment | 122 |
| Start date | Jun 26, 2015 |
| Primary completion | Jul 3, 2017 |
| Completion | Feb 22, 2019 |
| First posted | Jul 16, 2015 |
| Last update posted | Aug 21, 2020 |
| Countries | France, Georgia, Hungary, Moldova, Poland, Spain, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: